What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 (glucose-dependent insulinotropic polypeptide / glucagon-like peptide-1) receptor agonist. It is the first peptide to target both incretin receptors simultaneously, representing a novel approach to metabolic research.
The dual mechanism allows tirzepatide to leverage the complementary effects of both GIP and GLP-1 pathways. Research has shown synergistic effects on insulin secretion, glucagon regulation, appetite control, and energy metabolism.
With a half-life of approximately 5 days, tirzepatide is administered once weekly in research protocols.
Quick Reference
| Parameter | Value |
|---|---|
| Peptide Amount | 10mg |
| Recommended BAC Water | 2mL |
| Resulting Concentration | 5mg/mL (5000mcg/mL) |
| Typical Research Dose | 2.5mg - 15mg weekly |
| Frequency | Once weekly |
| Research Duration | 20-72 weeks |
Reconstitution Guide
Materials Needed
- Tirzepatide 10mg lyophilized vial
- Bacteriostatic water (BAC water)
- Insulin syringes (U-100, 29-31 gauge)
- Alcohol swabs
- Sharps container
Step-by-Step Instructions
-
Prepare your workspace — Clean your work area and gather all materials. Wash hands thoroughly.
-
Clean the vial stoppers — Wipe the Tirzepatide vial stopper and BAC water vial with alcohol swabs. Allow to dry.
-
Draw the BAC water — Using a sterile syringe, draw 2mL of bacteriostatic water.
-
Add water to peptide vial — Insert the needle and slowly inject BAC water down the inside wall of the vial. Never spray directly onto the powder.
-
Allow to dissolve — Tirzepatide typically dissolves within 5-10 minutes. Gently swirl if needed — never shake.
-
Verify dissolution — Solution should be clear and colorless. Discard if cloudy or particles visible.
-
Label and store — Write reconstitution date on vial. Refrigerate immediately.
Dosage Protocol
Concentration Calculations
With 10mg peptide in 2mL BAC water:
- Concentration: 5mg/mL = 5000mcg/mL
- Per unit (U-100 syringe): 50mcg per unit
Common Dose Calculations
| Desired Dose | Draw Volume | Syringe Units |
|---|---|---|
| 2.5mg | 0.50mL | 50 units |
| 5.0mg | 1.00mL | 100 units |
| 7.5mg | 1.50mL | Use 2 draws |
| 10mg | 2.00mL | Use 2 draws |
| 12.5mg | 2.50mL | Use 3 draws |
| 15mg | 3.00mL | Use 3 draws |
Note: For doses requiring more than 1mL, split into multiple injections at different sites.
Suggested Titration Protocol
Tirzepatide research protocols employ gradual escalation:
| Week | Dose | Notes |
|---|---|---|
| 1-4 | 2.5mg | Initial titration |
| 5-8 | 5mg | First escalation |
| 9-12 | 7.5mg | Second escalation |
| 13-16 | 10mg | Third escalation |
| 17-20 | 12.5mg | Fourth escalation |
| 21+ | 15mg | Maximum dose (if tolerated) |
Important Notes:
- Minimum 4 weeks at each dose level before escalation
- Many protocols plateau at 10mg or 12.5mg
- Escalation based on research objectives and tolerance assessment
Injection Guide
Subcutaneous Administration
- Clean injection site with alcohol swab and let dry
- Pinch skin fold at abdomen, thigh, or upper arm
- Insert needle at 90° angle
- Inject slowly over 5-10 seconds
- Wait 10 seconds before withdrawing
- Apply gentle pressure — do not massage
Site Rotation
Rotate weekly between:
- Abdomen (preferred) — avoid 2-inch radius around navel
- Front/outer thigh
- Back of upper arm
Large Volume Injections
For doses above 5mg (>1mL volume):
- Split into 2-3 separate injections
- Use different sites for each injection
- Complete all injections within 15-minute window
Storage Requirements
Lyophilized (Powder Form)
- Temperature: -20°C (-4°F) or colder
- Duration: 2+ years
- Conditions: Protect from light and moisture
Reconstituted (Mixed with BAC Water)
- Temperature: 2-8°C (36-46°F)
- Duration: 4-6 weeks
- Conditions: Protect from light, never freeze
Critical Storage Notes
- Tirzepatide is temperature-sensitive — keep refrigerated
- Transport on ice packs if needed
- Discard if left at room temperature for extended periods
- Never use discolored or cloudy solutions
Research Considerations
Dual Mechanism of Action
Tirzepatide’s unique dual-receptor approach:
GIP Receptor Activation:
- Enhanced insulin secretion
- Improved beta-cell function
- Potential adipose tissue effects
GLP-1 Receptor Activation:
- Appetite suppression
- Delayed gastric emptying
- Glucagon suppression
Key Research Findings
Clinical trials (SURMOUNT, SURPASS programs) demonstrated:
- Superior weight reduction compared to selective GLP-1 agonists
- Significant glycemic improvements
- Favorable metabolic parameter changes
- Novel insights into incretin biology
Sourcing for Research
Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.
Scientific References
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387:205-216.
- Frías JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” N Engl J Med. 2021;385:503-515.
- Samms RJ, et al. “How May GIP Enhance the Therapeutic Efficacy of GLP-1?” Trends Endocrinol Metab. 2020;31:410-421.
Last updated: December 01, 2024
Disclaimer: This information is for educational and research purposes only. Tirzepatide as a research peptide is not intended for human consumption. Pharmaceutical tirzepatide (Mounjaro®, Zepbound®) requires a prescription. Always follow applicable laws and institutional guidelines.